Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Growth 2026-2032
The global Nectin-4-Directed Antibody Drug Conjugates (ADC) market size is predicted to grow from US$ 1746 million in 2025 to US$ 3330 million in 2032; it is expected to grow at a CAGR of 9.6% from 2026 to 2032.
In 2025, global Nectin-4-Directed Antibody Drug Conjugates (ADC) production reached approximately 961 K Units, with an average global market price of around 1857 USD per Unit.
Nectin-4–directed antibody–drug conjugates (ADCs) are targeted cancer therapies in which a monoclonal antibody that specifically binds the cell-surface protein Nectin-4 (PVRL4) is chemically linked (via a linker) to a cytotoxic payload. After the antibody binds Nectin-4 on tumor cells, the ADC is typically internalized, the linker is cleaved (or the antibody is degraded), and the payload is released inside the cell to kill the cancer cell .
Nectin-4–directed antibody–drug conjugates (ADCs) stand out because they combine a clinically validated tumor-associated target with the precision of antibody binding and the potency of a cytotoxic payload, addressing one of oncology’s most persistent pain points: how to deliver strong cell-killing therapy while limiting the broad, systemic damage seen with traditional chemotherapy. By exploiting Nectin-4 expression on certain epithelial tumors, these ADCs can concentrate drug exposure in malignant tissue, potentially improving the therapeutic window, enabling meaningful activity in patients who have exhausted standard options, and creating room for rational combinations that deepen and extend responses without simply escalating toxicity. The industry tailwinds are strong: continued demand for differentiated, high-value oncology assets; rapid maturation of linker and payload technologies that can fine-tune efficacy and tolerability; growing confidence from regulators and clinicians as ADC know-how improves; and a clear commercial incentive to develop targeted therapies that fit biomarker-driven treatment pathways and expand into earlier lines of therapy. Looking ahead, the Nectin-4 ADC space is evolving from a single-product story into a competitive innovation arena where next-generation designs aim to improve safety profiles, broaden eligible patient populations, and prove durability across additional tumor types, making it a compelling segment of the broader ADC market with credible momentum and a runway for sustained growth as clinical experience, manufacturing scale, and combination strategies continue to mature.
The upstream raw materials for Nectin-4-Directed Antibody Drug Conjugates (ADCs) mainly include antibodies, payloads, linkers, etc. Typical suppliers include Thermo Fisher, Merck, WuXi XDC, Porton, etc. The downstream applications are mainly in the treatment of diseases such as urothelial carcinoma, esophageal cancer, and triple-negative breast cancer.
The production capacity of Nectin-4-Directed Antibody Drug Conjugates (ADCs) varies greatly depending on the scale of antibody expression, the level of conjugation technology, and the formulation filling capacity. The gross profit margin of Nectin-4-Directed Antibody Drug Conjugates (ADCs) is in the range of 70%-80%.
United States market for Nectin-4-Directed Antibody Drug Conjugates (ADC) is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Nectin-4-Directed Antibody Drug Conjugates (ADC) is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Nectin-4-Directed Antibody Drug Conjugates (ADC) is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Nectin-4-Directed Antibody Drug Conjugates (ADC) players cover Astellas, Innate Pharma, Corbus Pharmaceuticals, BioAtla, Eli Lilly, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LP Information, Inc. (LPI) ' newest research report, the “Nectin-4-Directed Antibody Drug Conjugates (ADC) Industry Forecast” looks at past sales and reviews total world Nectin-4-Directed Antibody Drug Conjugates (ADC) sales in 2025, providing a comprehensive analysis by region and market sector of projected Nectin-4-Directed Antibody Drug Conjugates (ADC) sales for 2026 through 2032. With Nectin-4-Directed Antibody Drug Conjugates (ADC) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Nectin-4-Directed Antibody Drug Conjugates (ADC) industry.
This Insight Report provides a comprehensive analysis of the global Nectin-4-Directed Antibody Drug Conjugates (ADC) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Nectin-4-Directed Antibody Drug Conjugates (ADC) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Nectin-4-Directed Antibody Drug Conjugates (ADC) market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Nectin-4-Directed Antibody Drug Conjugates (ADC) and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Nectin-4-Directed Antibody Drug Conjugates (ADC).
This report presents a comprehensive overview, market shares, and growth opportunities of Nectin-4-Directed Antibody Drug Conjugates (ADC) market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
In 2025, global Nectin-4-Directed Antibody Drug Conjugates (ADC) production reached approximately 961 K Units, with an average global market price of around 1857 USD per Unit.
Nectin-4–directed antibody–drug conjugates (ADCs) are targeted cancer therapies in which a monoclonal antibody that specifically binds the cell-surface protein Nectin-4 (PVRL4) is chemically linked (via a linker) to a cytotoxic payload. After the antibody binds Nectin-4 on tumor cells, the ADC is typically internalized, the linker is cleaved (or the antibody is degraded), and the payload is released inside the cell to kill the cancer cell .
Nectin-4–directed antibody–drug conjugates (ADCs) stand out because they combine a clinically validated tumor-associated target with the precision of antibody binding and the potency of a cytotoxic payload, addressing one of oncology’s most persistent pain points: how to deliver strong cell-killing therapy while limiting the broad, systemic damage seen with traditional chemotherapy. By exploiting Nectin-4 expression on certain epithelial tumors, these ADCs can concentrate drug exposure in malignant tissue, potentially improving the therapeutic window, enabling meaningful activity in patients who have exhausted standard options, and creating room for rational combinations that deepen and extend responses without simply escalating toxicity. The industry tailwinds are strong: continued demand for differentiated, high-value oncology assets; rapid maturation of linker and payload technologies that can fine-tune efficacy and tolerability; growing confidence from regulators and clinicians as ADC know-how improves; and a clear commercial incentive to develop targeted therapies that fit biomarker-driven treatment pathways and expand into earlier lines of therapy. Looking ahead, the Nectin-4 ADC space is evolving from a single-product story into a competitive innovation arena where next-generation designs aim to improve safety profiles, broaden eligible patient populations, and prove durability across additional tumor types, making it a compelling segment of the broader ADC market with credible momentum and a runway for sustained growth as clinical experience, manufacturing scale, and combination strategies continue to mature.
The upstream raw materials for Nectin-4-Directed Antibody Drug Conjugates (ADCs) mainly include antibodies, payloads, linkers, etc. Typical suppliers include Thermo Fisher, Merck, WuXi XDC, Porton, etc. The downstream applications are mainly in the treatment of diseases such as urothelial carcinoma, esophageal cancer, and triple-negative breast cancer.
The production capacity of Nectin-4-Directed Antibody Drug Conjugates (ADCs) varies greatly depending on the scale of antibody expression, the level of conjugation technology, and the formulation filling capacity. The gross profit margin of Nectin-4-Directed Antibody Drug Conjugates (ADCs) is in the range of 70%-80%.
United States market for Nectin-4-Directed Antibody Drug Conjugates (ADC) is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Nectin-4-Directed Antibody Drug Conjugates (ADC) is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Nectin-4-Directed Antibody Drug Conjugates (ADC) is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Nectin-4-Directed Antibody Drug Conjugates (ADC) players cover Astellas, Innate Pharma, Corbus Pharmaceuticals, BioAtla, Eli Lilly, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LP Information, Inc. (LPI) ' newest research report, the “Nectin-4-Directed Antibody Drug Conjugates (ADC) Industry Forecast” looks at past sales and reviews total world Nectin-4-Directed Antibody Drug Conjugates (ADC) sales in 2025, providing a comprehensive analysis by region and market sector of projected Nectin-4-Directed Antibody Drug Conjugates (ADC) sales for 2026 through 2032. With Nectin-4-Directed Antibody Drug Conjugates (ADC) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Nectin-4-Directed Antibody Drug Conjugates (ADC) industry.
This Insight Report provides a comprehensive analysis of the global Nectin-4-Directed Antibody Drug Conjugates (ADC) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Nectin-4-Directed Antibody Drug Conjugates (ADC) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Nectin-4-Directed Antibody Drug Conjugates (ADC) market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Nectin-4-Directed Antibody Drug Conjugates (ADC) and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Nectin-4-Directed Antibody Drug Conjugates (ADC).
This report presents a comprehensive overview, market shares, and growth opportunities of Nectin-4-Directed Antibody Drug Conjugates (ADC) market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Cleavable Linkers
- Non-cleavable Linkers
- Microtubule inhibitors
- Topoisomerase Inhibitor
- Others
- Humanized IgG1
- Fc Silencing IgG1
- Bladder Cancer
- Esophageal Cancer
- Triple-negative Breast Cancer
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Astellas
- Innate Pharma
- Corbus Pharmaceuticals
- BioAtla
- Eli Lilly
- Adcentrx Therapeutics
- Mabwell
- Jiangsu Hengrui
- Cspc Holdings
- What is the 10-year outlook for the global Nectin-4-Directed Antibody Drug Conjugates (ADC) market?
- What factors are driving Nectin-4-Directed Antibody Drug Conjugates (ADC) market growth, globally and by region?
- Which technologies are poised for the fastest growth by market and region?
- How do Nectin-4-Directed Antibody Drug Conjugates (ADC) market opportunities vary by end market size?
- How does Nectin-4-Directed Antibody Drug Conjugates (ADC) break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Nectin-4-Directed Antibody Drug Conjugates (ADC) by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Nectin-4-Directed Antibody Drug Conjugates (ADC) by Country/Region, 2021, 2025 & 2032
2.2 Nectin-4-Directed Antibody Drug Conjugates (ADC) Segment by Type
2.2.1 Cleavable Linkers
2.2.2 Non-cleavable Linkers
2.2.3 Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Type
2.2.3.1 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Type (2021-2026)
2.2.3.2 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue and Market Share by Type (2021-2026)
2.2.3.3 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sale Price by Type (2021-2026)
2.3 Nectin-4-Directed Antibody Drug Conjugates (ADC) Segment by Payload Mechanism
2.3.1 Microtubule inhibitors
2.3.2 Topoisomerase Inhibitor
2.3.3 Others
2.3.4 Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Payload Mechanism
2.3.4.1 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Payload Mechanism (2021-2026)
2.3.4.2 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue and Market Share by Payload Mechanism (2021-2026)
2.3.4.3 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sale Price by Payload Mechanism (2021-2026)
2.4 Nectin-4-Directed Antibody Drug Conjugates (ADC) Segment by Antibody
2.4.1 Humanized IgG1
2.4.2 Fc Silencing IgG1
2.4.3 Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Antibody
2.4.3.1 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Antibody (2021-2026)
2.4.3.2 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue and Market Share by Antibody (2021-2026)
2.4.3.3 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sale Price by Antibody (2021-2026)
2.5 Nectin-4-Directed Antibody Drug Conjugates (ADC) Segment by Application
2.5.1 Bladder Cancer
2.5.2 Esophageal Cancer
2.5.3 Triple-negative Breast Cancer
2.5.4 Others
2.5.5 Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Application
2.5.5.1 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sale Market Share by Application (2021-2026)
2.5.5.2 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue and Market Share by Application (2021-2026)
2.5.5.3 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Breakdown Data by Company
3.1.1 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Annual Sales by Company (2021-2026)
3.1.2 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Company (2021-2026)
3.2 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Annual Revenue by Company (2021-2026)
3.2.1 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Company (2021-2026)
3.2.2 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Market Share by Company (2021-2026)
3.3 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sale Price by Company
3.4 Key Manufacturers Nectin-4-Directed Antibody Drug Conjugates (ADC) Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Nectin-4-Directed Antibody Drug Conjugates (ADC) Product Location Distribution
3.4.2 Players Nectin-4-Directed Antibody Drug Conjugates (ADC) Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR NECTIN-4-DIRECTED ANTIBODY DRUG CONJUGATES (ADC) BY GEOGRAPHIC REGION
4.1 World Historic Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Size by Geographic Region (2021-2026)
4.1.1 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Size by Country/Region (2021-2026)
4.2.1 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Annual Sales by Country/Region (2021-2026)
4.2.2 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Annual Revenue by Country/Region (2021-2026)
4.3 Americas Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Growth
4.4 APAC Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Growth
4.5 Europe Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Growth
4.6 Middle East & Africa Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Growth
5 AMERICAS
5.1 Americas Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Country
5.1.1 Americas Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Country (2021-2026)
5.1.2 Americas Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Country (2021-2026)
5.2 Americas Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Type (2021-2026)
5.3 Americas Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Region
6.1.1 APAC Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Region (2021-2026)
6.1.2 APAC Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Region (2021-2026)
6.2 APAC Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Type (2021-2026)
6.3 APAC Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Nectin-4-Directed Antibody Drug Conjugates (ADC) by Country
7.1.1 Europe Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Country (2021-2026)
7.1.2 Europe Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Country (2021-2026)
7.2 Europe Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Type (2021-2026)
7.3 Europe Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Nectin-4-Directed Antibody Drug Conjugates (ADC) by Country
8.1.1 Middle East & Africa Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Country (2021-2026)
8.1.2 Middle East & Africa Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Country (2021-2026)
8.2 Middle East & Africa Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Type (2021-2026)
8.3 Middle East & Africa Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Nectin-4-Directed Antibody Drug Conjugates (ADC)
10.3 Manufacturing Process Analysis of Nectin-4-Directed Antibody Drug Conjugates (ADC)
10.4 Industry Chain Structure of Nectin-4-Directed Antibody Drug Conjugates (ADC)
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Nectin-4-Directed Antibody Drug Conjugates (ADC) Distributors
11.3 Nectin-4-Directed Antibody Drug Conjugates (ADC) Customer
12 WORLD FORECAST REVIEW FOR NECTIN-4-DIRECTED ANTIBODY DRUG CONJUGATES (ADC) BY GEOGRAPHIC REGION
12.1 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Size Forecast by Region
12.1.1 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Forecast by Region (2027-2032)
12.1.2 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Forecast by Type (2027-2032)
12.7 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Astellas
13.1.1 Astellas Company Information
13.1.2 Astellas Nectin-4-Directed Antibody Drug Conjugates (ADC) Product Portfolios and Specifications
13.1.3 Astellas Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Astellas Main Business Overview
13.1.5 Astellas Latest Developments
13.2 Innate Pharma
13.2.1 Innate Pharma Company Information
13.2.2 Innate Pharma Nectin-4-Directed Antibody Drug Conjugates (ADC) Product Portfolios and Specifications
13.2.3 Innate Pharma Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Innate Pharma Main Business Overview
13.2.5 Innate Pharma Latest Developments
13.3 Corbus Pharmaceuticals
13.3.1 Corbus Pharmaceuticals Company Information
13.3.2 Corbus Pharmaceuticals Nectin-4-Directed Antibody Drug Conjugates (ADC) Product Portfolios and Specifications
13.3.3 Corbus Pharmaceuticals Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Corbus Pharmaceuticals Main Business Overview
13.3.5 Corbus Pharmaceuticals Latest Developments
13.4 BioAtla
13.4.1 BioAtla Company Information
13.4.2 BioAtla Nectin-4-Directed Antibody Drug Conjugates (ADC) Product Portfolios and Specifications
13.4.3 BioAtla Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 BioAtla Main Business Overview
13.4.5 BioAtla Latest Developments
13.5 Eli Lilly
13.5.1 Eli Lilly Company Information
13.5.2 Eli Lilly Nectin-4-Directed Antibody Drug Conjugates (ADC) Product Portfolios and Specifications
13.5.3 Eli Lilly Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Eli Lilly Main Business Overview
13.5.5 Eli Lilly Latest Developments
13.6 Adcentrx Therapeutics
13.6.1 Adcentrx Therapeutics Company Information
13.6.2 Adcentrx Therapeutics Nectin-4-Directed Antibody Drug Conjugates (ADC) Product Portfolios and Specifications
13.6.3 Adcentrx Therapeutics Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Adcentrx Therapeutics Main Business Overview
13.6.5 Adcentrx Therapeutics Latest Developments
13.7 Mabwell
13.7.1 Mabwell Company Information
13.7.2 Mabwell Nectin-4-Directed Antibody Drug Conjugates (ADC) Product Portfolios and Specifications
13.7.3 Mabwell Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Mabwell Main Business Overview
13.7.5 Mabwell Latest Developments
13.8 Jiangsu Hengrui
13.8.1 Jiangsu Hengrui Company Information
13.8.2 Jiangsu Hengrui Nectin-4-Directed Antibody Drug Conjugates (ADC) Product Portfolios and Specifications
13.8.3 Jiangsu Hengrui Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Jiangsu Hengrui Main Business Overview
13.8.5 Jiangsu Hengrui Latest Developments
13.9 Cspc Holdings
13.9.1 Cspc Holdings Company Information
13.9.2 Cspc Holdings Nectin-4-Directed Antibody Drug Conjugates (ADC) Product Portfolios and Specifications
13.9.3 Cspc Holdings Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Cspc Holdings Main Business Overview
13.9.5 Cspc Holdings Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Nectin-4-Directed Antibody Drug Conjugates (ADC) by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Nectin-4-Directed Antibody Drug Conjugates (ADC) by Country/Region, 2021, 2025 & 2032
2.2 Nectin-4-Directed Antibody Drug Conjugates (ADC) Segment by Type
2.2.1 Cleavable Linkers
2.2.2 Non-cleavable Linkers
2.2.3 Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Type
2.2.3.1 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Type (2021-2026)
2.2.3.2 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue and Market Share by Type (2021-2026)
2.2.3.3 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sale Price by Type (2021-2026)
2.3 Nectin-4-Directed Antibody Drug Conjugates (ADC) Segment by Payload Mechanism
2.3.1 Microtubule inhibitors
2.3.2 Topoisomerase Inhibitor
2.3.3 Others
2.3.4 Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Payload Mechanism
2.3.4.1 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Payload Mechanism (2021-2026)
2.3.4.2 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue and Market Share by Payload Mechanism (2021-2026)
2.3.4.3 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sale Price by Payload Mechanism (2021-2026)
2.4 Nectin-4-Directed Antibody Drug Conjugates (ADC) Segment by Antibody
2.4.1 Humanized IgG1
2.4.2 Fc Silencing IgG1
2.4.3 Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Antibody
2.4.3.1 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Antibody (2021-2026)
2.4.3.2 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue and Market Share by Antibody (2021-2026)
2.4.3.3 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sale Price by Antibody (2021-2026)
2.5 Nectin-4-Directed Antibody Drug Conjugates (ADC) Segment by Application
2.5.1 Bladder Cancer
2.5.2 Esophageal Cancer
2.5.3 Triple-negative Breast Cancer
2.5.4 Others
2.5.5 Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Application
2.5.5.1 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sale Market Share by Application (2021-2026)
2.5.5.2 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue and Market Share by Application (2021-2026)
2.5.5.3 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Breakdown Data by Company
3.1.1 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Annual Sales by Company (2021-2026)
3.1.2 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Company (2021-2026)
3.2 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Annual Revenue by Company (2021-2026)
3.2.1 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Company (2021-2026)
3.2.2 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Market Share by Company (2021-2026)
3.3 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sale Price by Company
3.4 Key Manufacturers Nectin-4-Directed Antibody Drug Conjugates (ADC) Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Nectin-4-Directed Antibody Drug Conjugates (ADC) Product Location Distribution
3.4.2 Players Nectin-4-Directed Antibody Drug Conjugates (ADC) Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR NECTIN-4-DIRECTED ANTIBODY DRUG CONJUGATES (ADC) BY GEOGRAPHIC REGION
4.1 World Historic Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Size by Geographic Region (2021-2026)
4.1.1 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Size by Country/Region (2021-2026)
4.2.1 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Annual Sales by Country/Region (2021-2026)
4.2.2 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Annual Revenue by Country/Region (2021-2026)
4.3 Americas Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Growth
4.4 APAC Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Growth
4.5 Europe Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Growth
4.6 Middle East & Africa Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Growth
5 AMERICAS
5.1 Americas Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Country
5.1.1 Americas Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Country (2021-2026)
5.1.2 Americas Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Country (2021-2026)
5.2 Americas Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Type (2021-2026)
5.3 Americas Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Region
6.1.1 APAC Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Region (2021-2026)
6.1.2 APAC Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Region (2021-2026)
6.2 APAC Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Type (2021-2026)
6.3 APAC Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Nectin-4-Directed Antibody Drug Conjugates (ADC) by Country
7.1.1 Europe Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Country (2021-2026)
7.1.2 Europe Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Country (2021-2026)
7.2 Europe Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Type (2021-2026)
7.3 Europe Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Nectin-4-Directed Antibody Drug Conjugates (ADC) by Country
8.1.1 Middle East & Africa Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Country (2021-2026)
8.1.2 Middle East & Africa Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Country (2021-2026)
8.2 Middle East & Africa Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Type (2021-2026)
8.3 Middle East & Africa Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Nectin-4-Directed Antibody Drug Conjugates (ADC)
10.3 Manufacturing Process Analysis of Nectin-4-Directed Antibody Drug Conjugates (ADC)
10.4 Industry Chain Structure of Nectin-4-Directed Antibody Drug Conjugates (ADC)
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Nectin-4-Directed Antibody Drug Conjugates (ADC) Distributors
11.3 Nectin-4-Directed Antibody Drug Conjugates (ADC) Customer
12 WORLD FORECAST REVIEW FOR NECTIN-4-DIRECTED ANTIBODY DRUG CONJUGATES (ADC) BY GEOGRAPHIC REGION
12.1 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Market Size Forecast by Region
12.1.1 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Forecast by Region (2027-2032)
12.1.2 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Forecast by Type (2027-2032)
12.7 Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Astellas
13.1.1 Astellas Company Information
13.1.2 Astellas Nectin-4-Directed Antibody Drug Conjugates (ADC) Product Portfolios and Specifications
13.1.3 Astellas Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Astellas Main Business Overview
13.1.5 Astellas Latest Developments
13.2 Innate Pharma
13.2.1 Innate Pharma Company Information
13.2.2 Innate Pharma Nectin-4-Directed Antibody Drug Conjugates (ADC) Product Portfolios and Specifications
13.2.3 Innate Pharma Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Innate Pharma Main Business Overview
13.2.5 Innate Pharma Latest Developments
13.3 Corbus Pharmaceuticals
13.3.1 Corbus Pharmaceuticals Company Information
13.3.2 Corbus Pharmaceuticals Nectin-4-Directed Antibody Drug Conjugates (ADC) Product Portfolios and Specifications
13.3.3 Corbus Pharmaceuticals Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Corbus Pharmaceuticals Main Business Overview
13.3.5 Corbus Pharmaceuticals Latest Developments
13.4 BioAtla
13.4.1 BioAtla Company Information
13.4.2 BioAtla Nectin-4-Directed Antibody Drug Conjugates (ADC) Product Portfolios and Specifications
13.4.3 BioAtla Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 BioAtla Main Business Overview
13.4.5 BioAtla Latest Developments
13.5 Eli Lilly
13.5.1 Eli Lilly Company Information
13.5.2 Eli Lilly Nectin-4-Directed Antibody Drug Conjugates (ADC) Product Portfolios and Specifications
13.5.3 Eli Lilly Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Eli Lilly Main Business Overview
13.5.5 Eli Lilly Latest Developments
13.6 Adcentrx Therapeutics
13.6.1 Adcentrx Therapeutics Company Information
13.6.2 Adcentrx Therapeutics Nectin-4-Directed Antibody Drug Conjugates (ADC) Product Portfolios and Specifications
13.6.3 Adcentrx Therapeutics Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Adcentrx Therapeutics Main Business Overview
13.6.5 Adcentrx Therapeutics Latest Developments
13.7 Mabwell
13.7.1 Mabwell Company Information
13.7.2 Mabwell Nectin-4-Directed Antibody Drug Conjugates (ADC) Product Portfolios and Specifications
13.7.3 Mabwell Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Mabwell Main Business Overview
13.7.5 Mabwell Latest Developments
13.8 Jiangsu Hengrui
13.8.1 Jiangsu Hengrui Company Information
13.8.2 Jiangsu Hengrui Nectin-4-Directed Antibody Drug Conjugates (ADC) Product Portfolios and Specifications
13.8.3 Jiangsu Hengrui Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Jiangsu Hengrui Main Business Overview
13.8.5 Jiangsu Hengrui Latest Developments
13.9 Cspc Holdings
13.9.1 Cspc Holdings Company Information
13.9.2 Cspc Holdings Nectin-4-Directed Antibody Drug Conjugates (ADC) Product Portfolios and Specifications
13.9.3 Cspc Holdings Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Cspc Holdings Main Business Overview
13.9.5 Cspc Holdings Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Nectin-4-Directed Antibody Drug Conjugates (ADC) Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Nectin-4-Directed Antibody Drug Conjugates (ADC) Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Cleavable Linkers
Table 4. Major Players of Non-cleavable Linkers
Table 5. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Type (2021-2026) & (K Units)
Table 6. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Type (2021-2026)
Table 7. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Type (2021-2026) & ($ million)
Table 8. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Market Share by Type (2021-2026)
Table 9. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sale Price by Type (2021-2026) & (US$/Unit)
Table 10. Major Players of Microtubule inhibitors
Table 11. Major Players of Topoisomerase Inhibitor
Table 12. Major Players of Others
Table 13. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Payload Mechanism (2021-2026) & (K Units)
Table 14. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Payload Mechanism (2021-2026)
Table 15. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Payload Mechanism (2021-2026) & ($ million)
Table 16. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Market Share by Payload Mechanism (2021-2026)
Table 17. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sale Price by Payload Mechanism (2021-2026) & (US$/Unit)
Table 18. Major Players of Humanized IgG1
Table 19. Major Players of Fc Silencing IgG1
Table 20. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Antibody (2021-2026) & (K Units)
Table 21. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Antibody (2021-2026)
Table 22. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Antibody (2021-2026) & ($ million)
Table 23. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Market Share by Antibody (2021-2026)
Table 24. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sale Price by Antibody (2021-2026) & (US$/Unit)
Table 25. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sale by Application (2021-2026) & (K Units)
Table 26. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sale Market Share by Application (2021-2026)
Table 27. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Application (2021-2026) & ($ million)
Table 28. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Market Share by Application (2021-2026)
Table 29. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sale Price by Application (2021-2026) & (US$/Unit)
Table 30. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Company (2021-2026) & (K Units)
Table 31. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Company (2021-2026)
Table 32. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Company (2021-2026) & ($ millions)
Table 33. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Market Share by Company (2021-2026)
Table 34. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sale Price by Company (2021-2026) & (US$/Unit)
Table 35. Key Manufacturers Nectin-4-Directed Antibody Drug Conjugates (ADC) Producing Area Distribution and Sales Area
Table 36. Players Nectin-4-Directed Antibody Drug Conjugates (ADC) Products Offered
Table 37. Nectin-4-Directed Antibody Drug Conjugates (ADC) Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 38. New Products and Potential Entrants
Table 39. Market M&A Activity & Strategy
Table 40. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Geographic Region (2021-2026) & (K Units)
Table 41. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share Geographic Region (2021-2026)
Table 42. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Geographic Region (2021-2026) & ($ millions)
Table 43. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Market Share by Geographic Region (2021-2026)
Table 44. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Country/Region (2021-2026) & (K Units)
Table 45. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Country/Region (2021-2026)
Table 46. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Country/Region (2021-2026) & ($ millions)
Table 47. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Market Share by Country/Region (2021-2026)
Table 48. Americas Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Country (2021-2026) & (K Units)
Table 49. Americas Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Country (2021-2026)
Table 50. Americas Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Country (2021-2026) & ($ millions)
Table 51. Americas Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Type (2021-2026) & (K Units)
Table 52. Americas Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Application (2021-2026) & (K Units)
Table 53. APAC Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Region (2021-2026) & (K Units)
Table 54. APAC Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Region (2021-2026)
Table 55. APAC Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Region (2021-2026) & ($ millions)
Table 56. APAC Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Type (2021-2026) & (K Units)
Table 57. APAC Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Application (2021-2026) & (K Units)
Table 58. Europe Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Country (2021-2026) & (K Units)
Table 59. Europe Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Country (2021-2026) & ($ millions)
Table 60. Europe Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Type (2021-2026) & (K Units)
Table 61. Europe Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Application (2021-2026) & (K Units)
Table 62. Middle East & Africa Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Country (2021-2026) & (K Units)
Table 63. Middle East & Africa Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Market Share by Country (2021-2026)
Table 64. Middle East & Africa Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Type (2021-2026) & (K Units)
Table 65. Middle East & Africa Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Application (2021-2026) & (K Units)
Table 66. Key Market Drivers & Growth Opportunities of Nectin-4-Directed Antibody Drug Conjugates (ADC)
Table 67. Key Market Challenges & Risks of Nectin-4-Directed Antibody Drug Conjugates (ADC)
Table 68. Key Industry Trends of Nectin-4-Directed Antibody Drug Conjugates (ADC)
Table 69. Nectin-4-Directed Antibody Drug Conjugates (ADC) Raw Material
Table 70. Key Suppliers of Raw Materials
Table 71. Nectin-4-Directed Antibody Drug Conjugates (ADC) Distributors List
Table 72. Nectin-4-Directed Antibody Drug Conjugates (ADC) Customer List
Table 73. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Forecast by Region (2027-2032) & (K Units)
Table 74. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Forecast by Region (2027-2032) & ($ millions)
Table 75. Americas Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Forecast by Country (2027-2032) & (K Units)
Table 76. Americas Nectin-4-Directed Antibody Drug Conjugates (ADC) Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 77. APAC Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Forecast by Region (2027-2032) & (K Units)
Table 78. APAC Nectin-4-Directed Antibody Drug Conjugates (ADC) Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 79. Europe Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Forecast by Country (2027-2032) & (K Units)
Table 80. Europe Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Forecast by Country (2027-2032) & ($ millions)
Table 81. Middle East & Africa Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Forecast by Country (2027-2032) & (K Units)
Table 82. Middle East & Africa Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Forecast by Country (2027-2032) & ($ millions)
Table 83. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Forecast by Type (2027-2032) & (K Units)
Table 84. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Forecast by Type (2027-2032) & ($ millions)
Table 85. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Forecast by Application (2027-2032) & (K Units)
Table 86. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Forecast by Application (2027-2032) & ($ millions)
Table 87. Astellas Basic Information, Nectin-4-Directed Antibody Drug Conjugates (ADC) Manufacturing Base, Sales Area and Its Competitors
Table 88. Astellas Nectin-4-Directed Antibody Drug Conjugates (ADC) Product Portfolios and Specifications
Table 89. Astellas Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 90. Astellas Main Business
Table 91. Astellas Latest Developments
Table 92. Innate Pharma Basic Information, Nectin-4-Directed Antibody Drug Conjugates (ADC) Manufacturing Base, Sales Area and Its Competitors
Table 93. Innate Pharma Nectin-4-Directed Antibody Drug Conjugates (ADC) Product Portfolios and Specifications
Table 94. Innate Pharma Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 95. Innate Pharma Main Business
Table 96. Innate Pharma Latest Developments
Table 97. Corbus Pharmaceuticals Basic Information, Nectin-4-Directed Antibody Drug Conjugates (ADC) Manufacturing Base, Sales Area and Its Competitors
Table 98. Corbus Pharmaceuticals Nectin-4-Directed Antibody Drug Conjugates (ADC) Product Portfolios and Specifications
Table 99. Corbus Pharmaceuticals Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 100. Corbus Pharmaceuticals Main Business
Table 101. Corbus Pharmaceuticals Latest Developments
Table 102. BioAtla Basic Information, Nectin-4-Directed Antibody Drug Conjugates (ADC) Manufacturing Base, Sales Area and Its Competitors
Table 103. BioAtla Nectin-4-Directed Antibody Drug Conjugates (ADC) Product Portfolios and Specifications
Table 104. BioAtla Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 105. BioAtla Main Business
Table 106. BioAtla Latest Developments
Table 107. Eli Lilly Basic Information, Nectin-4-Directed Antibody Drug Conjugates (ADC) Manufacturing Base, Sales Area and Its Competitors
Table 108. Eli Lilly Nectin-4-Directed Antibody Drug Conjugates (ADC) Product Portfolios and Specifications
Table 109. Eli Lilly Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 110. Eli Lilly Main Business
Table 111. Eli Lilly Latest Developments
Table 112. Adcentrx Therapeutics Basic Information, Nectin-4-Directed Antibody Drug Conjugates (ADC) Manufacturing Base, Sales Area and Its Competitors
Table 113. Adcentrx Therapeutics Nectin-4-Directed Antibody Drug Conjugates (ADC) Product Portfolios and Specifications
Table 114. Adcentrx Therapeutics Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 115. Adcentrx Therapeutics Main Business
Table 116. Adcentrx Therapeutics Latest Developments
Table 117. Mabwell Basic Information, Nectin-4-Directed Antibody Drug Conjugates (ADC) Manufacturing Base, Sales Area and Its Competitors
Table 118. Mabwell Nectin-4-Directed Antibody Drug Conjugates (ADC) Product Portfolios and Specifications
Table 119. Mabwell Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 120. Mabwell Main Business
Table 121. Mabwell Latest Developments
Table 122. Jiangsu Hengrui Basic Information, Nectin-4-Directed Antibody Drug Conjugates (ADC) Manufacturing Base, Sales Area and Its Competitors
Table 123. Jiangsu Hengrui Nectin-4-Directed Antibody Drug Conjugates (ADC) Product Portfolios and Specifications
Table 124. Jiangsu Hengrui Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 125. Jiangsu Hengrui Main Business
Table 126. Jiangsu Hengrui Latest Developments
Table 127. Cspc Holdings Basic Information, Nectin-4-Directed Antibody Drug Conjugates (ADC) Manufacturing Base, Sales Area and Its Competitors
Table 128. Cspc Holdings Nectin-4-Directed Antibody Drug Conjugates (ADC) Product Portfolios and Specifications
Table 129. Cspc Holdings Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 130. Cspc Holdings Main Business
Table 131. Cspc Holdings Latest Developments
Table 1. Nectin-4-Directed Antibody Drug Conjugates (ADC) Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Nectin-4-Directed Antibody Drug Conjugates (ADC) Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Cleavable Linkers
Table 4. Major Players of Non-cleavable Linkers
Table 5. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Type (2021-2026) & (K Units)
Table 6. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Type (2021-2026)
Table 7. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Type (2021-2026) & ($ million)
Table 8. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Market Share by Type (2021-2026)
Table 9. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sale Price by Type (2021-2026) & (US$/Unit)
Table 10. Major Players of Microtubule inhibitors
Table 11. Major Players of Topoisomerase Inhibitor
Table 12. Major Players of Others
Table 13. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Payload Mechanism (2021-2026) & (K Units)
Table 14. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Payload Mechanism (2021-2026)
Table 15. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Payload Mechanism (2021-2026) & ($ million)
Table 16. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Market Share by Payload Mechanism (2021-2026)
Table 17. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sale Price by Payload Mechanism (2021-2026) & (US$/Unit)
Table 18. Major Players of Humanized IgG1
Table 19. Major Players of Fc Silencing IgG1
Table 20. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Antibody (2021-2026) & (K Units)
Table 21. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Antibody (2021-2026)
Table 22. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Antibody (2021-2026) & ($ million)
Table 23. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Market Share by Antibody (2021-2026)
Table 24. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sale Price by Antibody (2021-2026) & (US$/Unit)
Table 25. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sale by Application (2021-2026) & (K Units)
Table 26. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sale Market Share by Application (2021-2026)
Table 27. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Application (2021-2026) & ($ million)
Table 28. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Market Share by Application (2021-2026)
Table 29. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sale Price by Application (2021-2026) & (US$/Unit)
Table 30. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Company (2021-2026) & (K Units)
Table 31. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Company (2021-2026)
Table 32. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Company (2021-2026) & ($ millions)
Table 33. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Market Share by Company (2021-2026)
Table 34. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sale Price by Company (2021-2026) & (US$/Unit)
Table 35. Key Manufacturers Nectin-4-Directed Antibody Drug Conjugates (ADC) Producing Area Distribution and Sales Area
Table 36. Players Nectin-4-Directed Antibody Drug Conjugates (ADC) Products Offered
Table 37. Nectin-4-Directed Antibody Drug Conjugates (ADC) Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 38. New Products and Potential Entrants
Table 39. Market M&A Activity & Strategy
Table 40. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Geographic Region (2021-2026) & (K Units)
Table 41. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share Geographic Region (2021-2026)
Table 42. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Geographic Region (2021-2026) & ($ millions)
Table 43. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Market Share by Geographic Region (2021-2026)
Table 44. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Country/Region (2021-2026) & (K Units)
Table 45. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Country/Region (2021-2026)
Table 46. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Country/Region (2021-2026) & ($ millions)
Table 47. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Market Share by Country/Region (2021-2026)
Table 48. Americas Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Country (2021-2026) & (K Units)
Table 49. Americas Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Country (2021-2026)
Table 50. Americas Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Country (2021-2026) & ($ millions)
Table 51. Americas Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Type (2021-2026) & (K Units)
Table 52. Americas Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Application (2021-2026) & (K Units)
Table 53. APAC Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Region (2021-2026) & (K Units)
Table 54. APAC Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Region (2021-2026)
Table 55. APAC Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Region (2021-2026) & ($ millions)
Table 56. APAC Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Type (2021-2026) & (K Units)
Table 57. APAC Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Application (2021-2026) & (K Units)
Table 58. Europe Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Country (2021-2026) & (K Units)
Table 59. Europe Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Country (2021-2026) & ($ millions)
Table 60. Europe Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Type (2021-2026) & (K Units)
Table 61. Europe Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Application (2021-2026) & (K Units)
Table 62. Middle East & Africa Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Country (2021-2026) & (K Units)
Table 63. Middle East & Africa Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Market Share by Country (2021-2026)
Table 64. Middle East & Africa Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Type (2021-2026) & (K Units)
Table 65. Middle East & Africa Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Application (2021-2026) & (K Units)
Table 66. Key Market Drivers & Growth Opportunities of Nectin-4-Directed Antibody Drug Conjugates (ADC)
Table 67. Key Market Challenges & Risks of Nectin-4-Directed Antibody Drug Conjugates (ADC)
Table 68. Key Industry Trends of Nectin-4-Directed Antibody Drug Conjugates (ADC)
Table 69. Nectin-4-Directed Antibody Drug Conjugates (ADC) Raw Material
Table 70. Key Suppliers of Raw Materials
Table 71. Nectin-4-Directed Antibody Drug Conjugates (ADC) Distributors List
Table 72. Nectin-4-Directed Antibody Drug Conjugates (ADC) Customer List
Table 73. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Forecast by Region (2027-2032) & (K Units)
Table 74. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Forecast by Region (2027-2032) & ($ millions)
Table 75. Americas Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Forecast by Country (2027-2032) & (K Units)
Table 76. Americas Nectin-4-Directed Antibody Drug Conjugates (ADC) Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 77. APAC Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Forecast by Region (2027-2032) & (K Units)
Table 78. APAC Nectin-4-Directed Antibody Drug Conjugates (ADC) Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 79. Europe Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Forecast by Country (2027-2032) & (K Units)
Table 80. Europe Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Forecast by Country (2027-2032) & ($ millions)
Table 81. Middle East & Africa Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Forecast by Country (2027-2032) & (K Units)
Table 82. Middle East & Africa Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Forecast by Country (2027-2032) & ($ millions)
Table 83. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Forecast by Type (2027-2032) & (K Units)
Table 84. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Forecast by Type (2027-2032) & ($ millions)
Table 85. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Forecast by Application (2027-2032) & (K Units)
Table 86. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Forecast by Application (2027-2032) & ($ millions)
Table 87. Astellas Basic Information, Nectin-4-Directed Antibody Drug Conjugates (ADC) Manufacturing Base, Sales Area and Its Competitors
Table 88. Astellas Nectin-4-Directed Antibody Drug Conjugates (ADC) Product Portfolios and Specifications
Table 89. Astellas Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 90. Astellas Main Business
Table 91. Astellas Latest Developments
Table 92. Innate Pharma Basic Information, Nectin-4-Directed Antibody Drug Conjugates (ADC) Manufacturing Base, Sales Area and Its Competitors
Table 93. Innate Pharma Nectin-4-Directed Antibody Drug Conjugates (ADC) Product Portfolios and Specifications
Table 94. Innate Pharma Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 95. Innate Pharma Main Business
Table 96. Innate Pharma Latest Developments
Table 97. Corbus Pharmaceuticals Basic Information, Nectin-4-Directed Antibody Drug Conjugates (ADC) Manufacturing Base, Sales Area and Its Competitors
Table 98. Corbus Pharmaceuticals Nectin-4-Directed Antibody Drug Conjugates (ADC) Product Portfolios and Specifications
Table 99. Corbus Pharmaceuticals Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 100. Corbus Pharmaceuticals Main Business
Table 101. Corbus Pharmaceuticals Latest Developments
Table 102. BioAtla Basic Information, Nectin-4-Directed Antibody Drug Conjugates (ADC) Manufacturing Base, Sales Area and Its Competitors
Table 103. BioAtla Nectin-4-Directed Antibody Drug Conjugates (ADC) Product Portfolios and Specifications
Table 104. BioAtla Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 105. BioAtla Main Business
Table 106. BioAtla Latest Developments
Table 107. Eli Lilly Basic Information, Nectin-4-Directed Antibody Drug Conjugates (ADC) Manufacturing Base, Sales Area and Its Competitors
Table 108. Eli Lilly Nectin-4-Directed Antibody Drug Conjugates (ADC) Product Portfolios and Specifications
Table 109. Eli Lilly Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 110. Eli Lilly Main Business
Table 111. Eli Lilly Latest Developments
Table 112. Adcentrx Therapeutics Basic Information, Nectin-4-Directed Antibody Drug Conjugates (ADC) Manufacturing Base, Sales Area and Its Competitors
Table 113. Adcentrx Therapeutics Nectin-4-Directed Antibody Drug Conjugates (ADC) Product Portfolios and Specifications
Table 114. Adcentrx Therapeutics Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 115. Adcentrx Therapeutics Main Business
Table 116. Adcentrx Therapeutics Latest Developments
Table 117. Mabwell Basic Information, Nectin-4-Directed Antibody Drug Conjugates (ADC) Manufacturing Base, Sales Area and Its Competitors
Table 118. Mabwell Nectin-4-Directed Antibody Drug Conjugates (ADC) Product Portfolios and Specifications
Table 119. Mabwell Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 120. Mabwell Main Business
Table 121. Mabwell Latest Developments
Table 122. Jiangsu Hengrui Basic Information, Nectin-4-Directed Antibody Drug Conjugates (ADC) Manufacturing Base, Sales Area and Its Competitors
Table 123. Jiangsu Hengrui Nectin-4-Directed Antibody Drug Conjugates (ADC) Product Portfolios and Specifications
Table 124. Jiangsu Hengrui Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 125. Jiangsu Hengrui Main Business
Table 126. Jiangsu Hengrui Latest Developments
Table 127. Cspc Holdings Basic Information, Nectin-4-Directed Antibody Drug Conjugates (ADC) Manufacturing Base, Sales Area and Its Competitors
Table 128. Cspc Holdings Nectin-4-Directed Antibody Drug Conjugates (ADC) Product Portfolios and Specifications
Table 129. Cspc Holdings Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 130. Cspc Holdings Main Business
Table 131. Cspc Holdings Latest Developments
LIST OF FIGURES
Figure 1. Picture of Nectin-4-Directed Antibody Drug Conjugates (ADC)
Figure 2. Nectin-4-Directed Antibody Drug Conjugates (ADC) Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Country/Region (2025)
Figure 10. Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Cleavable Linkers
Figure 12. Product Picture of Non-cleavable Linkers
Figure 13. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Type in 2026
Figure 14. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Market Share by Type (2021-2026)
Figure 15. Product Picture of Microtubule inhibitors
Figure 16. Product Picture of Topoisomerase Inhibitor
Figure 17. Product Picture of Others
Figure 18. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Payload Mechanism in 2026
Figure 19. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Market Share by Payload Mechanism (2021-2026)
Figure 20. Product Picture of Humanized IgG1
Figure 21. Product Picture of Fc Silencing IgG1
Figure 22. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Antibody in 2026
Figure 23. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Market Share by Antibody (2021-2026)
Figure 24. Nectin-4-Directed Antibody Drug Conjugates (ADC) Consumed in Bladder Cancer
Figure 25. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Market: Bladder Cancer (2021-2026) & (K Units)
Figure 26. Nectin-4-Directed Antibody Drug Conjugates (ADC) Consumed in Esophageal Cancer
Figure 27. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Market: Esophageal Cancer (2021-2026) & (K Units)
Figure 28. Nectin-4-Directed Antibody Drug Conjugates (ADC) Consumed in Triple-negative Breast Cancer
Figure 29. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Market: Triple-negative Breast Cancer (2021-2026) & (K Units)
Figure 30. Nectin-4-Directed Antibody Drug Conjugates (ADC) Consumed in Others
Figure 31. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Market: Others (2021-2026) & (K Units)
Figure 32. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sale Market Share by Application (2025)
Figure 33. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Market Share by Application in 2026
Figure 34. Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Company in 2026 (K Units)
Figure 35. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Company in 2026
Figure 36. Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Company in 2026 ($ millions)
Figure 37. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Market Share by Company in 2026
Figure 38. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Geographic Region (2021-2026)
Figure 39. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Market Share by Geographic Region in 2026
Figure 40. Americas Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales 2021-2026 (K Units)
Figure 41. Americas Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue 2021-2026 ($ millions)
Figure 42. APAC Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales 2021-2026 (K Units)
Figure 43. APAC Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue 2021-2026 ($ millions)
Figure 44. Europe Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales 2021-2026 (K Units)
Figure 45. Europe Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue 2021-2026 ($ millions)
Figure 46. Middle East & Africa Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales 2021-2026 (K Units)
Figure 47. Middle East & Africa Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue 2021-2026 ($ millions)
Figure 48. Americas Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Country in 2026
Figure 49. Americas Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Market Share by Country (2021-2026)
Figure 50. Americas Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Type (2021-2026)
Figure 51. Americas Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Application (2021-2026)
Figure 52. United States Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth 2021-2026 ($ millions)
Figure 53. Canada Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth 2021-2026 ($ millions)
Figure 54. Mexico Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth 2021-2026 ($ millions)
Figure 55. Brazil Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth 2021-2026 ($ millions)
Figure 56. APAC Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Region in 2026
Figure 57. APAC Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Market Share by Region (2021-2026)
Figure 58. APAC Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Type (2021-2026)
Figure 59. APAC Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Application (2021-2026)
Figure 60. China Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth 2021-2026 ($ millions)
Figure 61. Japan Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth 2021-2026 ($ millions)
Figure 62. South Korea Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth 2021-2026 ($ millions)
Figure 63. Southeast Asia Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth 2021-2026 ($ millions)
Figure 64. India Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth 2021-2026 ($ millions)
Figure 65. Australia Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth 2021-2026 ($ millions)
Figure 66. China Taiwan Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth 2021-2026 ($ millions)
Figure 67. Europe Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Country in 2026
Figure 68. Europe Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Market Share by Country (2021-2026)
Figure 69. Europe Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Type (2021-2026)
Figure 70. Europe Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Application (2021-2026)
Figure 71. Germany Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth 2021-2026 ($ millions)
Figure 72. France Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth 2021-2026 ($ millions)
Figure 73. UK Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth 2021-2026 ($ millions)
Figure 74. Italy Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth 2021-2026 ($ millions)
Figure 75. Russia Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth 2021-2026 ($ millions)
Figure 76. Middle East & Africa Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Country (2021-2026)
Figure 77. Middle East & Africa Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Type (2021-2026)
Figure 78. Middle East & Africa Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Application (2021-2026)
Figure 79. Egypt Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth 2021-2026 ($ millions)
Figure 80. South Africa Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth 2021-2026 ($ millions)
Figure 81. Israel Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth 2021-2026 ($ millions)
Figure 82. Turkey Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth 2021-2026 ($ millions)
Figure 83. GCC Countries Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth 2021-2026 ($ millions)
Figure 84. Manufacturing Cost Structure Analysis of Nectin-4-Directed Antibody Drug Conjugates (ADC) in 2026
Figure 85. Manufacturing Process Analysis of Nectin-4-Directed Antibody Drug Conjugates (ADC)
Figure 86. Industry Chain Structure of Nectin-4-Directed Antibody Drug Conjugates (ADC)
Figure 87. Channels of Distribution
Figure 88. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Forecast by Region (2027-2032)
Figure 89. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Market Share Forecast by Region (2027-2032)
Figure 90. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share Forecast by Type (2027-2032)
Figure 91. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Market Share Forecast by Type (2027-2032)
Figure 92. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share Forecast by Application (2027-2032)
Figure 93. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of Nectin-4-Directed Antibody Drug Conjugates (ADC)
Figure 2. Nectin-4-Directed Antibody Drug Conjugates (ADC) Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Country/Region (2025)
Figure 10. Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Cleavable Linkers
Figure 12. Product Picture of Non-cleavable Linkers
Figure 13. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Type in 2026
Figure 14. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Market Share by Type (2021-2026)
Figure 15. Product Picture of Microtubule inhibitors
Figure 16. Product Picture of Topoisomerase Inhibitor
Figure 17. Product Picture of Others
Figure 18. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Payload Mechanism in 2026
Figure 19. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Market Share by Payload Mechanism (2021-2026)
Figure 20. Product Picture of Humanized IgG1
Figure 21. Product Picture of Fc Silencing IgG1
Figure 22. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Antibody in 2026
Figure 23. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Market Share by Antibody (2021-2026)
Figure 24. Nectin-4-Directed Antibody Drug Conjugates (ADC) Consumed in Bladder Cancer
Figure 25. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Market: Bladder Cancer (2021-2026) & (K Units)
Figure 26. Nectin-4-Directed Antibody Drug Conjugates (ADC) Consumed in Esophageal Cancer
Figure 27. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Market: Esophageal Cancer (2021-2026) & (K Units)
Figure 28. Nectin-4-Directed Antibody Drug Conjugates (ADC) Consumed in Triple-negative Breast Cancer
Figure 29. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Market: Triple-negative Breast Cancer (2021-2026) & (K Units)
Figure 30. Nectin-4-Directed Antibody Drug Conjugates (ADC) Consumed in Others
Figure 31. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Market: Others (2021-2026) & (K Units)
Figure 32. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sale Market Share by Application (2025)
Figure 33. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Market Share by Application in 2026
Figure 34. Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales by Company in 2026 (K Units)
Figure 35. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Company in 2026
Figure 36. Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue by Company in 2026 ($ millions)
Figure 37. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Market Share by Company in 2026
Figure 38. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Geographic Region (2021-2026)
Figure 39. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Market Share by Geographic Region in 2026
Figure 40. Americas Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales 2021-2026 (K Units)
Figure 41. Americas Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue 2021-2026 ($ millions)
Figure 42. APAC Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales 2021-2026 (K Units)
Figure 43. APAC Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue 2021-2026 ($ millions)
Figure 44. Europe Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales 2021-2026 (K Units)
Figure 45. Europe Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue 2021-2026 ($ millions)
Figure 46. Middle East & Africa Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales 2021-2026 (K Units)
Figure 47. Middle East & Africa Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue 2021-2026 ($ millions)
Figure 48. Americas Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Country in 2026
Figure 49. Americas Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Market Share by Country (2021-2026)
Figure 50. Americas Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Type (2021-2026)
Figure 51. Americas Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Application (2021-2026)
Figure 52. United States Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth 2021-2026 ($ millions)
Figure 53. Canada Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth 2021-2026 ($ millions)
Figure 54. Mexico Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth 2021-2026 ($ millions)
Figure 55. Brazil Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth 2021-2026 ($ millions)
Figure 56. APAC Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Region in 2026
Figure 57. APAC Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Market Share by Region (2021-2026)
Figure 58. APAC Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Type (2021-2026)
Figure 59. APAC Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Application (2021-2026)
Figure 60. China Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth 2021-2026 ($ millions)
Figure 61. Japan Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth 2021-2026 ($ millions)
Figure 62. South Korea Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth 2021-2026 ($ millions)
Figure 63. Southeast Asia Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth 2021-2026 ($ millions)
Figure 64. India Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth 2021-2026 ($ millions)
Figure 65. Australia Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth 2021-2026 ($ millions)
Figure 66. China Taiwan Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth 2021-2026 ($ millions)
Figure 67. Europe Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Country in 2026
Figure 68. Europe Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Market Share by Country (2021-2026)
Figure 69. Europe Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Type (2021-2026)
Figure 70. Europe Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Application (2021-2026)
Figure 71. Germany Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth 2021-2026 ($ millions)
Figure 72. France Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth 2021-2026 ($ millions)
Figure 73. UK Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth 2021-2026 ($ millions)
Figure 74. Italy Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth 2021-2026 ($ millions)
Figure 75. Russia Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth 2021-2026 ($ millions)
Figure 76. Middle East & Africa Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Country (2021-2026)
Figure 77. Middle East & Africa Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Type (2021-2026)
Figure 78. Middle East & Africa Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share by Application (2021-2026)
Figure 79. Egypt Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth 2021-2026 ($ millions)
Figure 80. South Africa Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth 2021-2026 ($ millions)
Figure 81. Israel Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth 2021-2026 ($ millions)
Figure 82. Turkey Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth 2021-2026 ($ millions)
Figure 83. GCC Countries Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Growth 2021-2026 ($ millions)
Figure 84. Manufacturing Cost Structure Analysis of Nectin-4-Directed Antibody Drug Conjugates (ADC) in 2026
Figure 85. Manufacturing Process Analysis of Nectin-4-Directed Antibody Drug Conjugates (ADC)
Figure 86. Industry Chain Structure of Nectin-4-Directed Antibody Drug Conjugates (ADC)
Figure 87. Channels of Distribution
Figure 88. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Forecast by Region (2027-2032)
Figure 89. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Market Share Forecast by Region (2027-2032)
Figure 90. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share Forecast by Type (2027-2032)
Figure 91. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Market Share Forecast by Type (2027-2032)
Figure 92. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Sales Market Share Forecast by Application (2027-2032)
Figure 93. Global Nectin-4-Directed Antibody Drug Conjugates (ADC) Revenue Market Share Forecast by Application (2027-2032)
